Novo nordisk receives complete response letter in the us for once-weekly basal insulin icodec

BagsvÆrd, denmark, 10 july 2024 – novo nordisk today announced that the us food and drug administration (fda) has issued a complete response letter (crl) covering the biologics license application for once-weekly basal insulin icodec for the treatment of diabetes mellitus.
NVO Ratings Summary
NVO Quant Ranking